Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia : A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia..

Medienart:

Klinische Studie

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

ClinicalTrials.gov - (2024) vom: 23. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Phase: Phase 3
Pneumonia
Pneumonia, Bacterial
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: March 3, 2021, Last downloaded: ClinicalTrials.gov processed this data on February 28, 2024, Last updated: February 28, 2024

Study ID:

NCT04779242
PTK0796-CABP-19302

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG003692108